Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia

Affiliations

¹ Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland.
² Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
³ Department of Translational Medicine, Division of Hematology, University of Eastern Piedmont, Novara, Italy.
⁴ Hematology Institute, Catholic University of the Sacred Hearth, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy.
⁵ Ospedale di Circolo of Varese & Department of Medicine and Surgery, Hematology, ASST Sette Laghi, University of Insubria, Varese, Italy.
⁶ Division of Hematology, Cantonal Hospital of Lucerne, Lucerne, Switzerland.
⁷ Strategic Research Program on CLL, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy.
⁸ Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.
⁹ Clinic of Haematology, University Hospital Basel, Basel, Switzerland.
¹⁰ Institute of Oncology Research, Bellinzona, Switzerland.
¹¹ Clinic of Oncology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
¹² Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.
¹³ Clinic of Hematology, Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.

Comment

Gabriela Forestieri et al. Hematol Oncol. 2022 Dec.

. 2022 Dec;40(5):1100-1104.

doi: 10.1002/hon.3032. Epub 2022 Jun 1.

¹ Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland.
² Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
³ Department of Translational Medicine, Division of Hematology, University of Eastern Piedmont, Novara, Italy.
⁴ Hematology Institute, Catholic University of the Sacred Hearth, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy.
⁵ Ospedale di Circolo of Varese & Department of Medicine and Surgery, Hematology, ASST Sette Laghi, University of Insubria, Varese, Italy.
⁶ Division of Hematology, Cantonal Hospital of Lucerne, Lucerne, Switzerland.
⁷ Strategic Research Program on CLL, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy.
⁸ Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.
⁹ Clinic of Haematology, University Hospital Basel, Basel, Switzerland.
¹⁰ Institute of Oncology Research, Bellinzona, Switzerland.
¹¹ Clinic of Oncology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
¹² Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.
¹³ Clinic of Hematology, Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.

No abstract available

Keywords: chronic lymphocytic leukemia; dose intensity; ibrutinib.

Comment on

A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia.
Chen LS, Bose P, Cruz ND, Jiang Y, Wu Q, Thompson PA, Feng S, Kroll MH, Qiao W, Huang X, Jain N, Wierda WG, Keating MJ, Gandhi V. Chen LS, et al. Blood. 2018 Nov 22;132(21):2249-2259. doi: 10.1182/blood-2018-06-860593. Epub 2018 Sep 25. Blood. 2018. PMID: 30254130 Free PMC article. Clinical Trial.

1. Ahn IE, Tian X, Ipe D, et al. Prediction of outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: development and validation of a four-factor prognostic model. J Clin Oncol. 2021;39(6):576-585. https://doi.org/10.1200/jco.20.00979
1. Winqvist M, Asklid A, Andersson PO, et al. Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group. Haematologica. 2016;101(12):1573-1580. https://doi.org/10.3324/haematol.2016.144576
1. Forum UC. Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients. Haematologica. 2016;101(12):1563-1572. https://doi.org/10.3324/haematol.2016.147900
1. Akhtar OS, Attwood K, Lund I, Hare R, Hernandez-Ilizaliturri FJ, Torka P. Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2019;60(7):1650-1655. https://doi.org/10.1080/10428194.2018.1554862
1. Mato AR, Timlin C, Ujjani C, et al. Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-centre study. Br J Haematol. 2018;181(2):259-261. https://doi.org/10.1111/bjh.14540